#1 Clinical Trials Search in Europe

GLYCYL-TYROSINE

Clinical trials investigating GLYCYL-TYROSINE are studying a living donor kidney transplant setting. The trial aims to evaluate kidney function and renal reserve in both donors and recipients after transplantation. It focuses on adults in a renal transplantation programme and measures whether kidney function changes over time.

Table of contents

Trial overview

The trial titled PREDONATION RENAL RESERVE is an interventional study in a living donor renal transplantation programme.[1] It is authorised and plans to include 60 participants.[1]

The study is designed to evaluate the evolution of kidney function after transplant in both the donor and the recipient.[1] The brief summary says the researchers want to understand how pre-donation kidney function and renal reserve in the donor relate to kidney function after transplantation.[1]

Who is studied

The target population is people in a living donor kidney transplant programme.[1] This means the trial involves both the person who donates the kidney and the person who receives it.[1]

The source data do not list detailed age limits, sex limits, or other entry rules.[1] Based on the trial record, the main focus is on donor-recipient pairs in renal transplantation.[1]

What is measured

The main outcome is the change in renal function in both donor and recipient after transplantation.[1] Renal function means how well the kidneys filter the blood and remove waste.[1]

Kidney function is measured with a reference test called plasma clearance of iohexol.[1] This is a standard way to check how well the kidneys clear a substance from the blood.[1]

The trial also measures renal reserve using an intravenous infusion of an amino acid solution.[1] Renal reserve is the kidney’s ability to increase its work when the body needs more filtering power.[1]

The intervention listed in the record is Nephrotect solución para perfusión, given intravascularly.[1] The trial record does not provide more detail on how this intervention is used in the study beyond its listing.[1]

Trial design and phase

This is an interventional study, which means researchers are giving a study intervention and then measuring outcomes.[1] The trial is in Phase 3, a later stage of clinical research that studies the question in a larger group of people.[1]

The status is listed as Authorised.[1] The planned enrollment is 60 participants, which suggests a focused study rather than a very large one.[1]

What these terms mean for patients

For patients, this trial is about whether kidney function changes after a living donor transplant and whether the donor’s kidney reserve before donation helps explain those changes.[1] The study uses measured lab-based tests instead of only symptoms or routine checks.[1]

Because the trial record is limited, it does not tell us the final results, detailed eligibility rules, or whether the study has finished.[1] It does show that the research is centered on donor and recipient kidney outcomes after transplantation.[1]

Trial ID Phase Condition studied Status Enrollment
2024-519757-11-00 Phase 3 Renal transplantation, living donor Authorised 60

FAQ

  • What is being studied in GLYCYL-TYROSINE clinical trials? The trial is studying kidney function after living donor renal transplantation. It also looks at renal reserve, which means how well the kidneys can increase their work when needed.
  • Who may take part in this trial? The study is in a living donor renal transplantation programme. It involves both kidney donors and the people who receive the kidney.
  • What phase is the GLYCYL-TYROSINE trial? The trial is listed as Phase 3. This means it is testing the study question in a larger group of people and looking closely at outcomes.
  • What condition is the trial focused on? The condition studied is renal transplantation with a living donor. The trial looks at how kidney function evolves after the transplant.
  • What outcome is being measured? The main outcome is the change in kidney function in both donor and recipient after transplant. Kidney function is measured with a reference test called plasma clearance of iohexol, and renal reserve is assessed by an intravenous amino acid infusion.

Ongoing Clinical Trials on GLYCYL-TYROSINE

Unfortunately, we did not find any clinical trials matching the selected criteria. Try changing the filter settings or broadening the search criteria to see more available research participation opportunities.

Glossary

  • Renal transplantation: A kidney transplant, which is surgery to place a healthy kidney into a person whose kidneys do not work well enough.
  • Living donor: A person who donates a kidney while alive.
  • Donor: The person who gives the kidney in a transplant.
  • Recipient: The person who receives the donated kidney.
  • Renal function: How well the kidneys are working.
  • Renal reserve: The kidney’s ability to increase its work when the body needs more filtering power.
  • Plasma clearance of iohexol: A reference test used to measure kidney filtering function more accurately.
  • Intravenous infusion: A fluid given through a vein.
  • Interventional study: A clinical trial where researchers give a treatment or procedure and then measure the results.
  • Phase 3: A later-stage trial that studies the treatment or procedure in a larger group of people.

References